Brief: Medicenna Announces EMA Approval Of Its Clinical Trial Application To Expand Its Phase 1/2 Ability-1 Study To Europe
26/06/2024 12:55
June 26 (Reuters) - Medicenna Therapeutics Corp
MDNA.TO :
* MEDICENNA ANNOUNCES EMA APPROVAL OF ITS CLINICAL TRIAL
APPLICATION TO EXPAND ITS PHASE 1/2 ABILITY-1 STUDY TO EUROPE
* MEDICENNA THERAPEUTICS CORP: MONOTHERAPY EXPANSION AND
COMBINATION ESCALATION DATA OF ABILITY-1 STUDY ARE EXPECTED IN
H2 2024
Source text for Eikon: ID:nGNX1GwlSN
Further company coverage: MDNA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results